Pregabalin Capsule
Product Images NDC 71610-871

This text provides a formula for estimating creatinine clearance (CLCr) using age, weight, and serum creatinine levels. It suggests multiplying the result of (1140 - age in years) and weight in kilograms to get an estimate for creatinine clearance. In addition, for female patients, it mentions that the product of 72 and serum creatinine concentration in mg/dL should be further multiplied by 0.85.*

This text provides a graphical representation in Figure 1 of patients achieving different levels of improvement in pain intensity in Study DPN 1. The chart shows the percentage of patients who experienced improvement in pain intensity when treated with Pregabalin at different dosages (200 mg three times a day, 100 mg three times a day, 25 mg three times a day) compared to those who received a Placebo. The y-axis denotes the percentage of patients improved, while the x-axis represents the percentage improvement in pain from baseline. This data helps in understanding the efficacy of Pregabalin at varying dosages in managing pain intensity in patients with diabetic peripheral neuropathy.*

This text provides data from a Fibromyalgia study comparing Pregabalin and Placebo in terms of Time to Loss of Therapeutic Response (LTR). The graph shows a Kaplan-Meier Analysis with the estimated percentage of subjects without LTR over time in days. The chart indicates that Pregabalin may have a positive impact on maintaining therapeutic response compared to Placebo.*

This text provides information about the percentage of subjects improved from baseline to week 12 in a study or research project. The data seems to be related to a study or evaluation involving subjects and their progress over a 12-week period.*

This text presents a figure showing patients achieving various levels of improvement in pain intensity in a study called DPN 2. The figure compares the effectiveness of Pregabalin 100 mg three times a day with a placebo in terms of the percentage of patients that experienced improvement in pain intensity from baseline.*

This data from Study PHN 1 shows the percentage of patients achieving different levels of improvement in pain intensity from baseline when prescribed different doses of pregabalin and a placebo. The graph depicts the effectiveness of pregabalin at doses of 75 mg, 150 mg, and 300 mg taken twice a day compared to a placebo. The results indicate a higher percentage of patients experienced pain relief with increasing doses of pregabalin.*

This data from Study PHN 2 illustrated in Figure 4 shows the percentage of patients achieving different levels of improvement in pain intensity with different treatments. Pregabalin at 200 mg three times a day led to the highest percentage of patients showing improvement, followed by pregabalin at 100 mg three times a day. The placebo group had the lowest percentage of improvement.*

This is a graph showing the percentage of patients achieving various levels of improvement in pain intensity in Study PHN 3. The graph compares the outcomes for patients taking Pregabalin 100 mg three times a day, Pregabalin 50 mg three times a day, and Placebo. The x-axis represents the percentage of patients improved, while the y-axis shows the percentage improvement in pain from baseline. This visual representation helps in understanding the effectiveness of different treatments in managing pain intensity.*

The text contains data points labeled as Study E1 and Study E3, numerical values indicating percentages, and a mention of "statistically significant vs placebo". It seems to be reporting on a comparison between different studies or treatments.*

The text mentions different responder rates for different treatments. It includes percentages for each treatment group, such as a 8%, 2%, and 26% response rate. It also references a placebo and specific dosage amounts in mg/kg/day. The information provided seems to pertain to a study or evaluation of different treatments and their effectiveness.*

This text provides data on the different levels of improvement in pain intensity achieved by patients in a fibromyalgia study. The percentages of patients experiencing improvement are compared across different daily doses of Pregabalin and a placebo. The graph shows how a 600 mg daily dose of Pregabalin had the highest percentage of patients reporting improvement, followed by the 450 mg and 300 mg doses, with the placebo having the lowest percentage.*